The report highlights Daiichi Sankyo's progress towards its 2025 Vision of becoming a ""Global Pharma Innovator with competitive advantage in oncology."" The company outlined its 5-year business plan, which includes key strategic targets like growing edoxaban, expanding U.S. businesses, and establishing an oncology business. The report also emphasizes the company's commitment to sustainable growth, evident in its focus on enhancing profit generation capabilities, streamlining assets, and increasing shareholder returns. Additionally, the report details Daiichi Sankyo's CSR initiatives, including promoting compliance management, fostering mutual growth between employees and the company, enhancing communication with stakeholders, prioritizing environmental management, improving access to healthcare, and conducting social contribution activities.
Go back to company
Daiichi Sankyo Co Ltd 2017 Value Report
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 3.02 MB
No. of Pages 59 pages
Reporting periodApril 1, 2016-March 31, 2017
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue